NOTICE: I love receiving your thoughts and feedback! PLEASE do leave your comments below, which allows these articles to be more widely read. Thanks so much!
Roche teams up with Diabeloop to advance the management of insulin pump therapy was reported by PRNewswire.com, 11 December 2020.
Roche today announced that it is partnering with the French MedTech company Diabeloop to advance the management of insulin pump therapy, creating new opportunities to lower the burden of constant insulin dose adjustment for people with diabetes and to improve therapy outcomes. The partnership marks Roche’s first step in the field of automated insulin delivery (AID) representing a milestone in Roche’s strategy of integrated Personalized Diabetes Management (iPDM).
“Everybody at Roche Diabetes Care is excited about the new partnership with Diabeloop. The technology of Diabeloop, based on a self-learning algorithm, is unique. We are convinced that the potential of the hybrid closed-loop systems will contribute to a more efficient and personalized approach of diabetes management,” said Marcel Gmuender, Global Head of Roche Diabetes Care.
“Reliable insulin delivery is a critical component in Diabeloop’s hybrid closed-loop systems embedding therapeutic artificial intelligence. The accuracy and reliability of Roche’s insulin pump portfolio perfectly fits our vision to personalize therapy to the physiology and lifestyle of people with diabetes, helping them to spend less time managing diabetes while improving time in range,” said Erik Huneker, Diabeloop founder and co-CEO. “We are looking forward to partnering with Roche and work together to individualise diabetes management,” concluded Marc Julien, co-CEO at Diabeloop.
Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions. They also own the rights to the original Medingo Solo Patch Pump.
SIZZLE REEL: First-look at the Dexcom G7 Continuous Glucose Monitor (slated for 2021)
First Outpatient Evaluation of the Omnipod 5 AID was released by Insulet Corporation, for submission to Diabetes Technology & Therapeutics … very exciting!
Conclusion: The Omnipod 5 System was safe and effective when used at glucose targets from 110 to 150mg/dL for 14 days at home in children and adults with type 1 diabetes.
Solving What Happens After Transplantation was published by JDRF.org, 10 November 2020 in Beta Cell Replacement, Research News.
Elad Sintov, Ph.D., is a JDRF-funded postdoctoral fellow in the laboratory of Doug Melton, Ph.D. (himself a JDRF grantee), at Harvard University. In 2014, Dr. Melton and his team published a strategy for generating insulin-producing beta cells from stem cells, providing a virtually unlimited supply for transplantation. But preventing immune rejection, without immunosuppressive drugs, remains a major challenge.
One avenue to overcome this is to produce the beta cells from stem cells that have been modified to be immune to a cellular attack. In other words, making insulin-producing beta cells unrecognizable to the immune system. Dr. Sintov aims to do that through genetic modification.
Watch this short video to Meet Dr. Elad Sintov
Rare Forms of Diabetes: a New Study was reported by Dr. Irl Hirsch for diaTribe.org, 14 December 2020.
The RADIANT study aims to define unusual forms of diabetes, to help diagnose and treat these conditions. RADIANT is recruiting people who have been diagnosed with diabetes but don’t fit the usual characteristics of type 1 or type 2 diabetes.
Many types of diabetes remain unknown – we call these “atypical diabetes.” The National Institute of Health (NIH) has funded a study called RADIANT (Rare and Atypical DIAbetes NeTwork). Its goal is to discover the rare and atypical forms of diabetes that have not yet been described. These forms are not well understood, are difficult to diagnose, and most important, may be difficult to treat. RADIANT hopes to develop diagnostic tests to identify people with rare forms of diabetes as well as treatments for these conditions.
Read more: Rare Forms of Diabetes: RADIANT Study